Cargando…
Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines
In omics sciences, many compounds are measured simultaneously in a sample in a single run. Such analytical performance opens up prospects for improving cellular cancer vaccines and other cell-based immunotherapeutics. This article provides an overview of proteomics technology, known as cell proteomi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963030/ https://www.ncbi.nlm.nih.gov/pubmed/36839983 http://dx.doi.org/10.3390/pharmaceutics15020661 |
_version_ | 1784896149945057280 |
---|---|
author | Lokhov, Petr G. Balashova, Elena E. Trifonova, Oxana P. Maslov, Dmitry L. Archakov, Alexander I. |
author_facet | Lokhov, Petr G. Balashova, Elena E. Trifonova, Oxana P. Maslov, Dmitry L. Archakov, Alexander I. |
author_sort | Lokhov, Petr G. |
collection | PubMed |
description | In omics sciences, many compounds are measured simultaneously in a sample in a single run. Such analytical performance opens up prospects for improving cellular cancer vaccines and other cell-based immunotherapeutics. This article provides an overview of proteomics technology, known as cell proteomic footprinting. The molecular phenotype of cells is highly variable, and their antigenic profile is affected by many factors, including cell isolation from the tissue, cell cultivation conditions, and storage procedures. This makes the therapeutic properties of cells, including those used in vaccines, unpredictable. Cell proteomic footprinting makes it possible to obtain controlled cell products. Namely, this technology facilitates the cell authentication and quality control of cells regarding their molecular phenotype, which is directly connected with the antigenic properties of cell products. Protocols for cell proteomic footprinting with their crucial moments, footprint processing, and recommendations for the implementation of this technology are described in this paper. The provided footprints in this paper and program source code for their processing contribute to the fast implementation of this technology in the development and manufacturing of cell-based immunotherapeutics. |
format | Online Article Text |
id | pubmed-9963030 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99630302023-02-26 Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines Lokhov, Petr G. Balashova, Elena E. Trifonova, Oxana P. Maslov, Dmitry L. Archakov, Alexander I. Pharmaceutics Review In omics sciences, many compounds are measured simultaneously in a sample in a single run. Such analytical performance opens up prospects for improving cellular cancer vaccines and other cell-based immunotherapeutics. This article provides an overview of proteomics technology, known as cell proteomic footprinting. The molecular phenotype of cells is highly variable, and their antigenic profile is affected by many factors, including cell isolation from the tissue, cell cultivation conditions, and storage procedures. This makes the therapeutic properties of cells, including those used in vaccines, unpredictable. Cell proteomic footprinting makes it possible to obtain controlled cell products. Namely, this technology facilitates the cell authentication and quality control of cells regarding their molecular phenotype, which is directly connected with the antigenic properties of cell products. Protocols for cell proteomic footprinting with their crucial moments, footprint processing, and recommendations for the implementation of this technology are described in this paper. The provided footprints in this paper and program source code for their processing contribute to the fast implementation of this technology in the development and manufacturing of cell-based immunotherapeutics. MDPI 2023-02-16 /pmc/articles/PMC9963030/ /pubmed/36839983 http://dx.doi.org/10.3390/pharmaceutics15020661 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Lokhov, Petr G. Balashova, Elena E. Trifonova, Oxana P. Maslov, Dmitry L. Archakov, Alexander I. Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines |
title | Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines |
title_full | Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines |
title_fullStr | Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines |
title_full_unstemmed | Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines |
title_short | Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines |
title_sort | cell proteomic footprinting: advances in the quality of cellular and cell-derived cancer vaccines |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963030/ https://www.ncbi.nlm.nih.gov/pubmed/36839983 http://dx.doi.org/10.3390/pharmaceutics15020661 |
work_keys_str_mv | AT lokhovpetrg cellproteomicfootprintingadvancesinthequalityofcellularandcellderivedcancervaccines AT balashovaelenae cellproteomicfootprintingadvancesinthequalityofcellularandcellderivedcancervaccines AT trifonovaoxanap cellproteomicfootprintingadvancesinthequalityofcellularandcellderivedcancervaccines AT maslovdmitryl cellproteomicfootprintingadvancesinthequalityofcellularandcellderivedcancervaccines AT archakovalexanderi cellproteomicfootprintingadvancesinthequalityofcellularandcellderivedcancervaccines |